China bars GSK from national drug bulk-buy programme over drug irregularities
CHINA has blocked British drugmaker GSK from participating in its national drug procurement programme from Oct 31, 2022 to Apr 29, 2024, state television CCTV reported on Monday (Oct 31).
CCTV said authorities had decided to do so after a batch of dutasteride soft capsules supplied by GSK failed a recent quality check by the National Medical Products Administration.
GSK did not immediately respond to a request for comment.
Beijing runs a national scheme where global pharmaceutical companies and Chinese generic drugmakers vie to sell their products in bulk at public hospitals. REUTERS
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Share with us your feedback on BT's products and services
TRENDING NOW
‘We’ll look at it, we’ll see what is feasible’: SIA CEO on new business-class seat colours
SIA Q2 net profit quadruples to S$209.7 million on better unit revenue, lower Air India losses
Higher rates, weaker spending: Is the Philippines entering stagflation?
The limits of China’s trade concessions to Europe